Janus Henderson Group PLC Akero Therapeutics, Inc. Transaction History
Janus Henderson Group PLC
- $174 Billion
- Q1 2025
A detailed history of Janus Henderson Group PLC transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Janus Henderson Group PLC holds 7,068,648 shares of AKRO stock, worth $364 Million. This represents 0.16% of its overall portfolio holdings.
Number of Shares
7,068,648
Previous 6,034,239
17.14%
Holding current value
$364 Million
Previous $168 Million
70.45%
% of portfolio
0.16%
Previous 0.09%
Shares
24 transactions
Others Institutions Holding AKRO
# of Institutions
271Shares Held
86MCall Options Held
1.02MPut Options Held
823K-
Rtw Investments, LP New York, NY7.42MShares$382 Million4.92% of portfolio
-
Wellington Management Group LLP Boston, MA5.94MShares$306 Million0.05% of portfolio
-
Black Rock Inc. New York, NY5.59MShares$288 Million0.0% of portfolio
-
General Atlantic LLC New York, NY5.23MShares$270 Million7.15% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.82MShares$248 Million0.02% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $2.39B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...